Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Plus Toripalimab and Sequential Chemotherapy in HR+/HER2-low Breast Cancer
NCT06389006Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in breast cancer, sponsored by RemeGen. Primary endpoint: Total Pathological Complete Response. Started Apr 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06389006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389006.